Insider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Sells 15,000 Shares of Stock

by · The Markets Daily

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) Director Beth C. Seidenberg sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $48.03, for a total value of $720,450.00. Following the transaction, the director now directly owns 131,553 shares of the company’s stock, valued at approximately $6,318,490.59. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Vera Therapeutics Stock Performance

Shares of VERA traded down $2.33 during trading hours on Wednesday, hitting $40.64. The stock had a trading volume of 2,944,431 shares, compared to its average volume of 901,597. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.43 and a quick ratio of 21.43. Vera Therapeutics, Inc. has a 12 month low of $9.68 and a 12 month high of $50.78. The firm has a market capitalization of $2.23 billion, a PE ratio of -18.39 and a beta of 1.00. The stock has a fifty day moving average price of $40.40 and a 200 day moving average price of $38.89.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Analysts anticipate that Vera Therapeutics, Inc. will post -2.57 EPS for the current year.

Analyst Ratings Changes

VERA has been the subject of a number of research analyst reports. Guggenheim lifted their target price on Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Monday. JPMorgan Chase & Co. lifted their target price on Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 target price on shares of Vera Therapeutics in a report on Tuesday, October 1st. Scotiabank initiated coverage on Vera Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 target price for the company. Finally, Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $53.56.

Read Our Latest Analysis on VERA

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Avoro Capital Advisors LLC purchased a new position in Vera Therapeutics during the first quarter valued at $227,027,000. Price T Rowe Associates Inc. MD purchased a new position in Vera Therapeutics during the first quarter valued at $103,189,000. Vanguard Group Inc. lifted its position in Vera Therapeutics by 31.5% during the first quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock valued at $92,653,000 after purchasing an additional 515,106 shares in the last quarter. Samlyn Capital LLC lifted its position in Vera Therapeutics by 90.8% during the second quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after purchasing an additional 586,410 shares in the last quarter. Finally, First Light Asset Management LLC lifted its position in Vera Therapeutics by 130.6% during the second quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock valued at $36,387,000 after purchasing an additional 569,590 shares in the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

About Vera Therapeutics

(Get Free Report)

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Further Reading